Background
Smoking-induced damage to the cardiovascular system has been shown in many studies; however, the degree of damage varies from individual to individual. We hypothesized that the −930 a/G CYBA gene polymorphism in the NaDPh oxidase influences the association between cigarette smoking and carotid intima-media thickness (IMT) in young healthy adults.
Methods

cross-sectional data obtained in 2001 for the cardiovascular Risk in
Young Finns Study were used. IMT was measured with ultrasound. The genotyping was performed using a 5′-nuclease assay. a linear regression model was used to test whether the interaction between smoking and the genotypes was associated with IMT. The magnitude of the interaction effect was further examined by performing a stratified analysis according to smoking habits.
results
In the entire population, the mean and maxima IMT were higher in smokers than nonsmokers (P = 0.005 and 0.008, respectively). The differences were most significant in subjects with the GG genotype, borderline significant for the Ga genotype, and nonsignificant for the aa genotype. The interaction of genotypes with smoking was associated with mean and maximal IMT (P = 0.042 and 0.022). among smokers, subjects with the GG genotype had a higher mean and maximal IMT compared with carriers of the a allele (P = 0.021 and 0.012). In contrast, the mean and maximal IMT were lower for G allele carriers than subjects with the aa genotype among nonsmokers (P = 0.022 and 0.026). all results had been adjusted for potential risk factors related to IMT.
conclusion
The −930 a/G polymorphism modifies the association between cigarette smoking and IMT in young healthy adults. functional CYBA polymorphisms, which were in a low or moderate linkage disequilibrium. 12 Although the association of this polymorphism with cardiovascular diseases is controversial, the presence of the −930 A/G CYBA polymorphism has been related to higher transcriptional activity, mRNA and protein expression of the p22phox as well as the NADPH oxidase activity. [13] [14] [15] [16] [17] Previous studies have shown that the expression of the p22phox in human atherosclerotic coronary arteries is more intense than in nonatherosclerotic arteries, indicating possible participation of upregulated p22phox in the pathogenesis of atherosclerosis. 18 Therefore, it is likely that the genetic effect of the −930 A/G CYBA polymorphism may cause a between-individual difference in susceptibility to atherogenesis because of its relation with the p22phox.
Carotid intima-media thickness (IMT) is a marker of subclinical atherosclerosis. 19 Cigarette smoking is an important risk factor for the development of atherosclerosis. 20 Many studies on smoking and IMT have established a strong correlation between cigarette smoking and an accelerated progression of carotid atherosclerosis. 21, 22 Furthermore, we have previously shown that IMT values are higher among cigarette smokers than among nonsmokers in the Cardiovascular Risk in Young Finns Study. 23 In the present study, we further investigated the association of the −930 A/G CYBA polymorphism with IMT in response to cigarette smoking in the young Finns population. We hypothesized that the effect of the −930 A/G CYBA polymorphism of the NADPH oxidase modifies the atherosclerotic process and causes a between-individual difference in IMT in response to cigarette smoking.
Methods
Subjects. The Cardiovascular Risk in Young Finns
Study is an ongoing five-center, prospective cohort study regarding the cardiovascular risk in children and adolescents in Finland. The first cross-sectional survey was conducted in 1980 with 3,596 subjects aged 3-18 years. The latest 21-year follow-up was performed in 2001, enrolling 2,283 subjects aged 24-39 years from the original cohort. Thirty-six percent of the baseline cohort dropped out of the follow-up; the main reasons for nonparticipation have been analyzed previously. 23 In 2001, IMT was measured successfully for 2,264 subjects. In the present study, a total of 2,179 subjects were finally included in the analysis-85 were excluded due to missing data (n = 45) and unsuccessful genotyping (n = 40). All subjects provided a written informed consent in 2001, and the study was approved by the local ethics committees.
Clinical characteristics and risk factor measurements. Data including age, sex, and smoking habits were acquired using questionnaires. The category of smokers included both current and ex-smokers. Current smokers were defined as those who were currently smoking on a daily or weekly basis. Ex-smokers included those who reported regular smoking in the past but no current smoking. Pack-years were assessed for the smokers. Weight and height were measured and body mass index was calculated (kg/m 2 ). 24 Blood pressure (BP) in a sitting position was measured by trained research nurses after 5-min rest with a random zero sphygmomanometer. Korotkoff 's fifth sound was used as the sign of diastolic BP and first sound as the sign of systolic BP. The mean of three measurements on three different visits was used in the analysis. The subjects were defined as hypertensive if the systolic BP was ≥140 mm Hg and/or diastolic BP ≥90 mm Hg and/or if they had already been treated with drugs. Bloods were drawn for the biochemical and genetic analyses after an overnight fast. Standard enzymatic methods were employed for the determination of serum lipids and glucose. 24 Low-density lipoprotein cholesterol concentration was calculated with the Friedewald formula. The estimated glomerular filtration rate was calculated with the Cockroft-Gault formula. 25 Patients were defined as diabetic if their fasting blood glucose concentration was ≥126 mg/dl, and/or if they had already been diagnosed as diabetic. Fasting plasma highsensitive C-reactive protein concentrations were analyzed by means of latex turbidometric immunoassay (Wako Chemicals, Neuss, Germany).
DNA isolation and genotyping of the −930
A/G CYBA gene polymorphism. Whole venous bloods were drawn into EDTA tubes and then stored at −70 °C. Genomic DNA was extracted using a commercially available kit and the BioRobot M48 Workstation (Qiagen, Hilden, Germany) according to the manufacturer's instructions. Genotyping of the −930 A/G CYBA gene polymorphism (rs9932581) was performed for both PCR and allelic discrimination 26 using the ABI Prism 7900HT Sequence Detection System (Applied Biosystems, Foster City, CA). Nucleotide sequences for the primers and allele-specific probes were deduced from sequences published in the Gene Bank and Celera databases. The primer and probe design was carried out in conjugation with Applied Biosystems with the aid of the Assays by Design service. The reproducibility of polymorphism genotyping was 100%, as assessed by 94 blind duplicates.
Carotid artery measurements. Carotid ultrasound studies were performed using Sequoia 512 ultrasound mainframes (Acuson, Mountain View, CA) with 13.0 MHz linear array transducers. Details of the method have been described previously. 23 In brief, the posterior wall of the left carotid artery was scanned according to a standardized protocol. A 5-s moving scan was recorded and stored in digital format on optical disks for subsequent off-line analysis. The digitally stored scans were manually analyzed by a single reader blinded to the subjects' details, with the analyses performed using ultrasonic calipers. A minimum of four measurements of the carotid wall was taken to derive the mean and maximal IMT. To assess the reproducibility of IMT measurements, 60 participants were re-examined 3 months after the initial visit. The between-visit coefficient of variation for IMT measurements was 6.4%. To assess the reproducibility of IMT image analyses, 113 scans were reanalyzed by a second observer. The between-observer coefficient of variation was 5.2%.
Statistical analysis.
The continuous variables are presented as mean ± s.d. Differences across study groups were examined with the χ 2 -test for categorical variables, Student's t-test, and analysis of variance for continuous variables. A linear regression model was used to test the relation between IMT and the interaction of the −930 A/G CYBA polymorphism with smoking habits. For constructing the interaction variable (smoking × genotype), smoking and genotype were coded as follows: smoking, 1 for nonsmokers, 2 for smokers; genotype, 1 for GG, 2 for GA, 3 for AA. To select variables (potential risk factors) for the model, we first used the univariate linear regression method to filter out variables that associate with IMT individually. The variables we chose for the model included age, sex, body mass index, systolic BP, diastolic BP, blood glucose, total cholesterol, high-density lipoprotein cholesterol, lowdensity lipoprotein cholesterol, triglycerides, C-reactive protein, and estimated glomerular filtration rate. To further examine the interaction effect on IMT, stratified analysis according to smoking habits or genotype was performed using analysis of variance and covariance adjusted for the aforementioned risk factors. As some antihypertensive medications may influence the NADPH oxidase, all analyses were repeated after the exclusion of subjects taking these medications (n = 29), with similar results (data not shown). Due to skewed distributions, the values for triglycerides and C-reactive protein were log 10 -transformed and those for blood glucose reciprocal-transformed before the analyses. All statistical analyses were twosided and performed with the statistical software SPSS (version 14.0; SPSS, Chicago, IL). P values below 0.05 were considered statistically significant. In addition, power calculations were made with the freeware Power*G3. Post hoc power calculations for smokers revealed that we had 72 and 74% power to detect a difference of 0.013 and 0.05 mm in mean and maximal IMT, respectively, between subjects with the GG genotype and carriers of the A allele at a 5% significance level. For nonsmokers, we had 74 and 76% power at a 5% significance level to detect a difference of 0.019 and 0.087 mm in mean and maximal IMT, respectively, between subjects with the AA genotype and carriers of the G allele.
results
The study subjects formed a low-risk population: they were young, with 13.7% (n = 298) suffering from hypertension and 0.9% from diabetes (n = 20). However, many of the subjects (52.8%) had a smoking habit, and the pack-years in the entire population (n = 2,179) were 2.8 ± 5.5 (mean ± s.d.). Among smokers, the pack-years were significantly higher for current smokers than ex-smokers (6.5 ± 7.2 vs. 2.9 ± 4.8), and the result remained significant after adjusting for age and sex (P < 0.001). However, the pack-years did not correlate with carotid IMT after controlling for age and sex among the smokers (r = 0.019, P = 0.52 for maximal IMT; r = 0.016, P = 0.60 for mean IMT). Similarly, no correlation was found among current smokers or among ex-smokers (data not shown).
The characteristics of smokers (n = 1,151) and nonsmokers (n = 1,028) are shown in Table 1 . In the entire population, the prevalence of smoking was higher among male than female subjects. Differences were found in body mass index, estimated glomerular filtration rate, and the levels of triglycerides and high-density lipoprotein cholesterol between the smokers and nonsmokers, and the results remained after adjusting for age and/or sex.
The G allele frequency was 0.58 in this population, and the allele frequencies were in line with the Hardy-Weinberg equilibrium (χ 2 = 0.27, P = 0.33). The allele frequencies among Among all subjects, the mean and maximal IMT values were significantly higher among smokers, current smokers, or ex-smokers in comparison to nonsmokers (Table 3) , while no statistical difference was detected between current and exsmokers. The differences were most significant in subjects with the GG genotype, borderline significant for the GA genotype, and nonsignificant for the AA genotype ( Table 3 ). All these results remained similar after adjusting for potential risk factors including age, sex, body mass index, systolic BP, diastolic BP, blood glucose, total cholesterol, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, triglycerides, C-reactive protein, and estimated glomerular filtration rate ( Table 3) .
In the entire population, the interaction effect of the −930 A/G CYBA polymorphism and smoking on carotid IMT was examined with a linear regression model. The interaction-term (genotype × smoking) was significantly associated with mean and , and it remained significant (β = −0.168, P = 0.042 and β = −0.190, P = 0.022) when the model was further adjusted for the aforementioned risk factors. The magnitude of the interaction was further examined by performing a stratified analysis according to smoking habits. The mean and maximal IMT values were different between the genotypes both among smokers (P = 0.054 and P = 0.044, respectively) and among nonsmokers (P = 0.048 and P = 0.056, respectively, one-way analysis of variance), and the results remained significant after adjustment for the aforementioned risk factors in smokers (P = 0.047 and P = 0.039) and nonsmokers (P = 0.023 and P = 0.024, one-way analysis of covariance). Among smokers, subjects with the GG genotype had higher mean and maximal IMT values when compared with carriers of the A allele (GG vs. GA + AA, P = 0.024 and P = 0.014, respectively, one-way analysis of variance). In contrast, the mean and maximal IMT values were lower in carriers of the G allele than in subjects with the AA genotype among nonsmokers (GG + GA vs. AA, P = 0.015 and P = 0.018, respectively). The results remained significant after adjusting for the aforementioned risk factors among smokers (Figure 2 left-hand panel, P = 0.012 for maximal IMT and P = 0.021 for mean IMT, one-way analysis of covariance), as well as among nonsmokers (Figure 2 right-hand panel, P = 0.026 for maximal IMT and P = 0.022 for mean IMT).
discussion
In the present study, the association of cigarette smoking with IMT was influenced by the −930 A/G CYBA polymorphism of the NADPH oxidase. Our results showed that the effect of cigarette smoking impacted on IMT in G allele carries, but no effect was detected in subjects with the AA genotype, suggesting that the −930 A/G CYBA polymorphism might play an important role in modifying IMT in response to cigarette smoking. Cigarette smoking is known to induce a large amount of oxidants, and these free radicals could arise directly from cigarette smoke or indirectly from endogenous sources. 27, 28 In the setting of cardiovascular disease, a potentially more important source of reactive oxygen species is considered to derive from the substances in cigarette smoke that may stimulate intracellular reactive oxygen species production in the vasculature. [29] [30] [31] Recent studies demonstrated that cigarette smoke-induced superoxide production was released from the NADPH oxidase, but not from other inducible intracellular sources, such as xanthine oxidase or endothelial nitric oxide synthase. 30, 31 NADPH oxidase-mediated superoxide production has shown a significant correlation with IMT in subjects free of clinical atherosclerotic disease. 32 In the present study, IMT was significantly increased among smokers in comparison to nonsmokers. However, increased IMT in response to cigarette smoking varied between the genotypes of the −930 A/G CYBA polymorphism of the NADPH oxidase. Previously, the −930 A/G CYBA polymorphism had shown differential functional effects in the development of NADPH oxidase-dependent oxidative stress. 17 Therefore, our finding supports the hypothesis that cigarette smoking increases oxidative stress as a potential mechanism for initiating atherosclerosis, whereas the −930 A/G CYBA polymorphism of the NADPH oxidase seems to modify the atherosclerotic process and cause a between-individual difference in IMT in response to cigarette smoking. One additional finding of the present study was that the increased IMT value persisted in ex-smokers when compared with nonsmokers, and the −930 A/G CYBA polymorphism similarly impacted on the association between ex-smoking and IMT. Although some studies have shown that smoking cessation could revert the changes induced by cigarette smoking, 3, 33, 34 others have suggested that the reversible changes are time-dependent and that the smoking-related responses gradually subside after smoking cessation. 3, 34 The persisting effect of smoking after smoking cessation may keep ex-smokers in a condition of oxidative stress. 33, 35 Therefore, the effect of the −930 A/G CYBA polymorphism on IMT in the present study was highlighted among ex-smokers.
In the present study, the genetic effect on IMT differed in the presence and absence of cigarette smoking. The difference might be due to an interaction effect of cigarette smoking with the G allele of the −930 A/G CYBA polymorphism among smokers. The functional effect of the −930 A/G CYBA polymorphism has been studied in the phagocytic cells of healthy and hypertensive subjects. 16, 17, 36 The studies have consistently reported that the effect of the −930 A/G CYBA gene polymorphism on CYBA gene expression and subsequent activity depends on the hypertensive phenotype. 16, 17 In contrast, the effect of the −930 A/G polymorphism did not affect neutrophil NADPH oxidase activity in healthy adults. 36 The human p22phox promoter possesses several potential consensus sequences for transcriptional factors. 16 Because the −930 A/G polymorphic site lies on a potential binding site for CCAAT/enhancer binding proteins (C/EBPs) transcription factors, it has been suggested that upregulated C/EBP expression in essential hypertension might induce a greater effect on the transcriptional activity of the G than of the A allelic CYBA promoter. 16, 17 In the present study, the study subjects were young and formed a low-risk study population. Only 13.7% had hypertension, and no difference in BP values was observed between the smokers and nonsmokers. However, we found a significant effect of the −930 A/G CYBA polymorphism in G allele carriers depending on the exposure to cigarette smoking. It has been observed that the C/EBP-binding activity is significantly increased in healthy smokers when compared with nonsmokers. 37 It is therefore tempting to speculate a potential involvement of C/EBP in the NADPH oxidase activation among the smokers included the present study. Although we could not provide direct evidence of this, our findings that IMT in response to cigarette smoking was increased in G allele carriers while no change was found in subjects with the AA genotype were in concordance with this hypothesis.
In the present study, IMT was higher in subjects with the AA genotype than in G allele carriers among nonsmokers. This finding was not in concert with previous observations showing that there was no effect of the −930 A/G polymorphism on the NADPH oxidase activity in the healthy subjects with no cardiovascular risk factors and atherosclerotic burden. 16, 17, 36 We have no plausible explanation for this, but the differences in methodology between the present and previous studies might be behind this apparent discrepancy. All previous studies were conducted in vitro with the phagocytic cells obtained from healthy subjects for the study of the functional effect of the −930 A/G CYBA polymorphism. However, the values of IMT across the genotypes among the nonsmokers in our study might reflect physiological adaptations to various factors including the functional effect of the −930 A/G CYBA polymorphism in vascular tissues. The present study lacked the functional data on the effect of the −930 A/G CYBA polymorphism, whereas these functional data might be the useful intermediate phenotypes for predicting the relationship between the −930 A/G CYBA polymorphism and IMT. This is a limitation of the present study, and further investigations are required to elucidate the functional effect of the −930 A/G polymorphism on IMT variation.
Another limitation of the study is that we lost 36% of the baseline cohort in the follow-up phase. However, we have shown that the baseline risk factors were similar among participants and dropouts in the 21-year follow-up, and the present study cohort therefore seems to be representative of the original study population. 24 Furthermore, more females were represented among nonsmokers, but this is an unlikely source of bias because we adjusted our analyses by sex. Our study was based on a larger sample of young adults. However, the genetic effect was separately examined in the smoking and nonsmoking subgroups because of an interaction effect with cigarette smoking. Power calculations showed that we had ~75% power to detect the effect of the −930 A/G polymorphism on IMT in the subgroups. Therefore, our results need to be interpreted with caution and duplicated further with other similar populations.
The genetic effect of the −930 A/G CYBA polymorphism is associated with IMT in response to cigarette smoking among young healthy Finnish adults. 
